演題

RS1-14-9-4

治癒切除膵癌におけるSPARC発現と予後に関する検討

[演者] 村川 正明:1
[著者] 青山 徹:2, 渥美 陽介:1, 風間 慶祐:1, 山本 直人:1, 佐藤 勉:1,2, 吉川 貴己:1, 利野 靖:2, 益田 宗孝:2, 森永 聡一郎:1
1:神奈川県立がんセンター 消化器外科, 2:横浜市立大学医学部 外科治療学

Background: The predictive roles of secreted protein acidic and rich in cysteine (SPARC) in pancreatic adenocarcinoma (PDAC) patients after curative resection have not been clarified. We investigated the correlations between the stromal SPARC expression and the postoperative prognosis.
Methods:We retrospectively analyzed the clinical data from consecutive patients who underwent curative resection for pancreatic cancer in our institution from 2005 to 2014. Stromal SPARC expression was analyzed by immunohistochemistry on tumor tissue microarrays (TMAs) from the patients.
Results:179 patients were enrolled to this study. The median follow-up period of the present study was 62.1 months. 70 patients had positive stromal SPARC expression (39.1%). There were no significant difference between the positive stromal SPARC expression group and negative group. In survival analysis, there was significant difference in the 5-year overall survival (OS) rates after surgery, which were 8.1% and 19.8% between the stromal SPARC positive and negative groups, respectively (p=0.0316). Univariate analysis showed stromal SPARC expression, size of tumor, lymph node metastasis, and residual tumor as the possible prognostic factors. Multivariate analysis revealed stromal SPARC expression (hazard ratio (HR) =1.44 95%CI; 1.017-2.051), lymph node metastasis (HR=2.019 95%CI; 1.318-3.091), and residual tumor (HR=1.648 95%CI; 1.132-2.401) as the independent prognostic factor.
Conclusions:Stromal SPARC expression in resectable pancreatic cancer patients might be useful as the predictive survival marker. The prognostic value of stromal SPARC expression should be confirmed in another cohort or in a prospective multicenter-study.
詳細検索